GlassScriptPhysician profile
Geoffrey Scott Jensen
NPI 1518013143
$5,807.03
in general payments reported to CMS, 2019-2025
29 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $148 · 2021: $179 · 2022: $1,078 · 2023: $1,173 · 2024: $1,678 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,841 · Education: $47.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.84 |
| Education | $47.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.50 | 2019-2025 | |
| Celgene Corporation | $458.15 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $451.71 | 2019-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $296.35 | 2023-2025 | Omvoh |
| Pfizer INC. | $255.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.45 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $252.60 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $210.62 | 2022-2025 | |
| Genzyme Corporation | $193.73 | 2023-2025 | |
| Ardelyx, INC. | $169.70 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $136.52 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $106.51 | 2019-2024 | Ocaliva |
| Qol Medical, LLC | $95.50 | 2022-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $61.06 | 2019-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $53.06 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.00 | 2023-2025 | Dupixent |
| Sirtex Medical INC | $37.97 | 2019 | |
| Merck Sharp & Dohme LLC | $36.89 | 2019-2023 | Dificid |
| Conmed Corporation | $35.58 | 2024 | Conmed Generators |
| Celltrion USA INC. | $32.14 | 2024 | Zymfentra |
| Biocon Biologics INC | $28.52 | 2024 | Hulio |
| Ironwood Pharmaceuticals, INC | $28.37 | 2024 | |
| Phathom Pharmaceuticals, INC. | $27.70 | 2024-2025 | Voquezna |
| Mylan Institutional INC. | $23.24 | 2023 | Hulio |
| Aimmune Therapeutics, INC. | $15.85 | 2024 | |
| Shionogi INC | $15.83 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.78 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $11.80 | 2022 | |
| Organon LLC | $11.17 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.